on EMD Electronics (ETR:MRK)
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
On June 25, 2026, Merck KGaA announced a definitive agreement to acquire Bio-Techne Corporation, a leading provider of life science tools and technologies. Merck will purchase Bio-Techne for $73 per share in cash, valuing the deal at approximately $11.3 billion. This acquisition price represents a 36% premium over Bio-Techne's one-month average trading price.
Funding for this acquisition will come from Merck's existing cash reserves and new debt, while maintaining its investment-grade credit rating. The acquisition is subject to approval from Bio-Techne shareholders and regulatory authorities.
Merck's strategic move aims to enhance its position in the life sciences sector, with Bio-Techne's technologies strengthening its portfolio. The acquisition marks a significant development in the mergers and acquisitions landscape for both companies.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EMD Electronics news